New York Patent of the Month – July 2021

Narcolepsy is a neurological condition that causes rapid and unpredictable daytime sleepiness. It causes other symptoms as well, like sleep paralysis or hallucinations. With disrupted sleep, it further affects your psychological, social, and cognitive functioning. The current treatment options are variable in efficacy from patient to patient. Axsome Therapeutics, Inc. has developed a new treatment option using reboxetine – a known antidepressant.

The reboxetine treatment aims to tret those who experience narcolepsy with cataplexy which is sudden muscle weakness.The treatment plan administers a dose once daily for at least 14 days. After treatment, there is a reduction in the number of cataplexy attacks and a reduction in a variety of scales that indicate sleep levels. Some patients in clinical studies showed improved concentration abilities alongside reducing the number of inadvertent naps. Reboxetine is a highly selective norepinephrine reuptake inhibitor. Scientific studies show it can modulate noradrenergic activity, promoting wakefulness and helping maintain muscle tone. Axsome Therapeutics have a reboxetine treatment called AXS-12 which has been granted FDA Breakthrough Therapy designation for the treatment of narcolepsy. 

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts